NCT07387926 2026-02-04Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)NovartisPhase 1/2 Not yet recruiting50 enrolled
NCT07227311 2025-11-12A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)GlaxoSmithKlinePhase 2 Not yet recruiting200 enrolled
NCT06742138 2024-12-19To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple MyelomaQilu Pharmaceutical Co., Ltd.Phase 3 Not yet recruiting284 enrolled